Following last summer's go-ahead for its Phase III trial of PolyHeme, a hemoglobin-based oxygen carrier for hemorrhagic shock brought about by severe injury, Northfield Laboratories Inc. has priced an offering of 4.5 million shares at $15 each, for gross proceeds of about $67.5 million. (BioWorld Today) Read More
